Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Drluck2007 who wrote (33)	12/6/2007 1:54:04 PM
From: xcentral1	Respond to of 295

Pluristem Therapeutics Approved for Listing on NASDAQ Capital Market NEW YORK, Dec 06, 2007 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (OTCBB:PSTI) (DAX:PJT), a leading bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and auto-immune disorders, announced today that NASDAQ has approved the Company's application to list its securities on the NASDAQ Capital Market. The Company's common stock will begin trading on December 11, 2007 under the symbol PSTI. Zami Aberman, Pluristem's President and CEO commented, "Pluristem is proud to begin trading on the NASDAQ Capital Market system. We believe that NASDAQ is the right platform to support our business growth aspirations. I am confident that our listing will facilitate broader interest in our common stock from both institutional and individual investors." The NASDAQ listing approval is contingent upon the Company being in compliance with all applicable listing standards on the date it begins trading on NASDAQ, including that the trading price of the Company's common stock remain at $4.00 or more, and may be rescinded if the Company is not in compliance with such standards. About Pluristem Pluristem Therapeutics, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). Pluristem's products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta and not from embryonic stem cells. They are expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are believed to be immune-privileged, hence protecting the recipient from immunological reactions that often accompany transplantation. Pluristem has offices in the USA with research and manufacturing facilities in Israel.

To: Drluck2007 who wrote (33)	1/22/2008 11:10:39 AM
From: xcentral1	Respond to of 295

Dutton Associates Announces Investment Opinion: Pluristem Therapeutics Rated Speculative Buy in Update Report by Dutton Associates ROSEVILLE, Calif., Jan 22, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Pluristem Therapeutics, Inc. (Nasdaq:PSTI), with a Speculative Buy rating and 12-month price target of $6.50. The 17-page report by Dutton Associates senior analyst Denise T. Resnik is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and other leading financial portals. Pluristem Therapeutics' innovative cell therapy technology has the potential to enable blood from the umbilical cord and the placenta (retrieved after the birth of a baby) to become a viable alternative to stem cells harvested from donor bone marrow, with its intrinsic problems. While validation of the Company's technology is still in the pre-clinical stage, we believe that, if the technology proves to be successful, the impact on the patient population requiring bone marrow transplant would be significant, especially as therapeutic uses for such transplants continue to be discovered. As the Company makes progress in its clinical program -- specifically filing for Food and Drug Administration permission to conduct Phase 1 trials and commencing those trials -- we believe the shares will respond favorably. About Dutton Associates Dutton Associates is one of the largest independent investment research firms in the U.S. Its 27 senior analysts are primarily CFAs, have expertise in many industries. Dutton Associates provides continuing analyst coverage of 110 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The current cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $52,000 from the Company for 6 Research Reports with coverage commencing on 9/6/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

To: Drluck2007 who wrote (33)	2/19/2008 9:03:33 AM
From: xcentral1	Respond to of 295

Pluristem Therapeutics to Present its Clinical Trial Plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference BUSINESS WIRE Posted: 2008-02-19 08:24:27 NEW YORK--(BUSINESS WIRE)----Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that it will present its clinical trial plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California, USA. The presentation will take place on February 19th at 1 pm Pacific Time and will be web-cast live (at wsw.com and for 90 days following the presentation. Mr. Zami Aberman, Pluristem's Chairman and CEO commented, "We are very glad to have the opportunity to present our cutting edge cell therapy technology and our clinical programs at the Roth Capital Partners 20th Annual OC Growth Stock Conference. We strongly believe that our PLX cells can revolutionize the treatment of hematological malignancies and peripheral artery disease (PAD) and be therapeutically beneficial to millions of people. The Company is moving forward with its clinical programs and expects to announce its progress with the FDA and the EMEA (the Federal Drug Administration and the European Medicines Agency). Our target is to start our clinical trials in humans during 2008." About the Roth Capital Partners 20th Annual OC Growth Stock Conference Presented by ROTH Capital Partners February 18-21, 2008 @ The Ritz Carlton Laguna Niguel One Ritz-Carlton Drive Dana Point, California 92629 The Roth Capital Partners 20th Annual OC Growth Stock Conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California. The conference will consist of three focused days of presentations from over 300 small-cap companies. About Pluristem Pluristem Therapeutics Inc. is a company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). Pluristem's products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta, a non-controversial source, and not from embryonic stem cells. The MSCs are expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are believed to be immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantation. Pluristem has offices in the USA with research and manufacturing facilities in Israel.

To: Drluck2007 who wrote (33)	3/4/2008 8:36:04 AM
From: xcentral1	Respond to of 295

Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease BUSINESS WIRE Posted: 2008-03-04 08:22:01 NEW YORK--(BUSINESS WIRE)----Pluristem Therapeutics, Inc. (NASDAQ:PSTI) announced today that it has filed a Pre-Investigational New Drug (Pre-IND) application with the Paul Ehrlich Institute (PEI) in Germany for PLX-PAD, the Company's product for the treatment of Peripheral Artery Disease. The PEI is the German federal authority granting clinical trial approvals. PLX-PAD are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem's proprietary 3D PluriX(TM) technology. Pluristem has submitted a scientific package to the PEI. The package contains the results of a proof of concept study and preclinical study synopses utilizing PLX-PAD to support an IMPD (Investigational Medicinal Product Dossier) submission planned for later this year. This Pre-IND document also contains information concerning the process used to manufacture Pluristem's PLX-PAD product and the proposed clinical trial supporting the Company's IMPD. Zami Aberman, Pluristem's President & CEO, stated: "I am proud that our team has accomplished this important milestone in submitting this Pre-IND document as planned. I believe it represents the Pluristem team's ability and devotion to successfully meet the Company's goal of building a pipeline of PLX products, leading the Company to future achievements and prosperity." About Pluristem Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. The placental cells are expanded in the Company's proprietary PluriX(TM) 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors, or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent, and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, the PLX cells are immune-privileged and immunosuppressive, hence protecting the recipient from immunological reactions that often accompany transplantations. Pluristem's PLX-PAD is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). Pluristem has previously announced its PLX cells can be therapeutically beneficial in the treatment of a variety of other indications, such as ischemic stroke and Parkinson's disease (PD). The Company's PLX-I is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB). Pluristem has offices in the USA with research and manufacturing facilities in Israel.